Issue 3/2019
Content (10 Articles)
Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential
Anna Serafini, Elizabeth Gerard, Pierre Genton, Arielle Crespel, Philippe Gelisse
Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer’s and Parkinson’s Diseases
Andre F. Batista, Victor Bodart-Santos, Fernanda G. De Felice, Sergio T. Ferreira
Treatment Strategies for Clozapine-Induced Sialorrhea: A Systematic Review and Meta-analysis
Shih-Yu Chen, Gopi Ravindran, Qichen Zhang, Steve Kisely, Dan Siskind
Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis
Abdelrahman Elshafay, Truong Hong Hieu, Mohamed Fahmy Doheim, Mahmoud Attia Mohamed Kassem, Mohammed Fathi ELdoadoa, Sarah Keturah Holloway, Heba Abo-elghar, Kenji Hirayama, Nguyen Tien Huy
A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment
Brati Das, Riqiang Yan
Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development
Ariela Frieder, Madeleine Fersh, Rachel Hainline, Kristina M. Deligiannidis
A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy
Zeinab Gharaylou, Abbas Tafakhori, Elmira Agah, Vajihe Aghamollaii, Abbas Kebriaeezadeh, Mahmoudreza Hadjighassem
Comment on: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”
Georgios Tsivgoulis, Lina Palaiodimou, Aristeidis H. Katsanos, Konstantinos Voumvourakis, Georgios M. Hadjigeorgiou, Ioannis Heliopoulos, Theodore Karapanayiotides, Panagiotis Papathanasopoulos, Constantinos Kilidireas, Nikolaos Grigoriadis
Authors’ Reply to Tsivgoulis et al.: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”
Dimitrios Papadopoulos, Dimos-Dimitrios D. Mitsikostas
Correction to: Quantitative Pharmaco-Electroencephalography in Antiepileptic Drug Research
Yvonne Höller, Christoph Helmstaedter, Klaus Lehnertz